Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: Down-regulation of P-glycoprotein during metastatic progression

被引:0
作者
Komdeur, R
Molenaar, WM
Zwart, N
Hoekstra, HJ
Van den Berg, E
Van der Graaf, WTA
机构
[1] Univ Groningen Hosp, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Surg Oncol, NL-9700 RB Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Pathol, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen Hosp, Dept Med Genet, NL-9700 RB Groningen, Netherlands
关键词
multidrug resistance; soft-tissue sarcomas; metastasis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Chemotherapy sensitivity of soft-tissue sarcomas (STS) is limited, which may be due to multidrug resistance (MDR). MDR is associated with expression of P-glycoprotein (P-gp), Multidrug Resistance-associated Protein I (MRP1) and Lung Resistance-related Protein (LRP). It is unknown whether in STS metastasis is more resistant than the primary counterpart. Materials and Methods: In 35 chemonaive STS and their metastases (86% chemonaive), MDR proteins were immunohistochemically assessed. Eleven metastases presented synchronously, 24 metachronously. Expression was scored-positive (>5% positive tumour cells) or negative. Results: P-gp was positive in 31/34primaries (91%), versus 22132 metastases (69%) (p=0.005). This difference was significant for metachronous metastases (p = 0.008). MRP1 was positive in 18132 primaries (56%) and 22133 metastases (670%). MRP1 was more expressed in synchronous metastases than primaries (p = 0.047), but for the overall group this significance disappeared. LRP expression did not differ: 27/34 primanes (80%), versus 28134 metastases (82010). Conclusion: P-V, MRP1, LRP expression in the primary tumours was high. Metastatic progression did not coincide with MDR-protein up-regulation.
引用
收藏
页码:291 / 295
页数:5
相关论文
共 39 条
[1]   An oncological view on the blood-testis barrier [J].
Bart, J ;
Groen, HJM ;
van der Graaf, WTA ;
Hollema, H ;
Hendrikse, NH ;
Vaalburg, W ;
Sleijfer, DT ;
de Vries, EGE .
LANCET ONCOLOGY, 2002, 3 (06) :357-363
[2]   The multidrug resistance protein family [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1999, 1461 (02) :347-357
[3]   IMMUNOHISTOCHEMICAL DETECTION OF P-GLYCOPROTEIN - PROGNOSTIC CORRELATION IN SOFT-TISSUE SARCOMA OF CHILDHOOD [J].
CHAN, HSL ;
THORNER, PS ;
HADDAD, G ;
LING, V .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) :689-704
[4]   Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma [J].
Coley, HM ;
Verrill, MW ;
Gregson, SE ;
Odell, DE ;
Fisher, C ;
Judson, IR .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (07) :881-888
[5]   LYMPH-NODE METASTASIS FROM SOFT-TISSUE SARCOMA IN ADULTS - ANALYSIS OF DATA FROM A PROSPECTIVE DATABASE OF 1772 SARCOMA PATIENTS [J].
FONG, YM ;
COIT, DG ;
WOODRUFF, JM ;
BRENNAN, MF .
ANNALS OF SURGERY, 1993, 217 (01) :72-77
[6]   Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers [J].
Harada, T ;
Ogura, S ;
Yamazaki, K ;
Kinoshita, I ;
Itoh, T ;
Isobe, H ;
Yamashiro, K ;
Dosaka-Akita, H ;
Nishimura, M .
CANCER SCIENCE, 2003, 94 (04) :394-399
[7]  
Jager PL, 2000, CANCER, V89, P1726, DOI 10.1002/1097-0142(20001015)89:8<1726::AID-CNCR12>3.0.CO
[8]  
2-V
[9]  
Jimenez RE, 1999, CANCER-AM CANCER SOC, V86, P976, DOI 10.1002/(SICI)1097-0142(19990915)86:6<976::AID-CNCR12>3.0.CO
[10]  
2-3